全文获取类型
收费全文 | 30144篇 |
免费 | 3588篇 |
国内免费 | 1051篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 1141篇 |
妇产科学 | 139篇 |
基础医学 | 2119篇 |
口腔科学 | 94篇 |
临床医学 | 2862篇 |
内科学 | 4036篇 |
皮肤病学 | 187篇 |
神经病学 | 195篇 |
特种医学 | 679篇 |
外国民族医学 | 1篇 |
外科学 | 11672篇 |
综合类 | 4624篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 996篇 |
眼科学 | 26篇 |
药学 | 2403篇 |
16篇 | |
中国医学 | 3002篇 |
肿瘤学 | 570篇 |
出版年
2024年 | 136篇 |
2023年 | 813篇 |
2022年 | 1268篇 |
2021年 | 2163篇 |
2020年 | 1574篇 |
2019年 | 1648篇 |
2018年 | 1491篇 |
2017年 | 1480篇 |
2016年 | 1486篇 |
2015年 | 1485篇 |
2014年 | 2298篇 |
2013年 | 2321篇 |
2012年 | 1597篇 |
2011年 | 1787篇 |
2010年 | 1488篇 |
2009年 | 1321篇 |
2008年 | 1333篇 |
2007年 | 1210篇 |
2006年 | 1104篇 |
2005年 | 942篇 |
2004年 | 810篇 |
2003年 | 694篇 |
2002年 | 592篇 |
2001年 | 553篇 |
2000年 | 369篇 |
1999年 | 309篇 |
1998年 | 276篇 |
1997年 | 217篇 |
1996年 | 234篇 |
1995年 | 203篇 |
1994年 | 191篇 |
1993年 | 152篇 |
1992年 | 152篇 |
1991年 | 146篇 |
1990年 | 107篇 |
1989年 | 114篇 |
1988年 | 79篇 |
1987年 | 81篇 |
1986年 | 65篇 |
1985年 | 65篇 |
1984年 | 71篇 |
1983年 | 39篇 |
1982年 | 52篇 |
1981年 | 49篇 |
1980年 | 33篇 |
1979年 | 45篇 |
1978年 | 33篇 |
1977年 | 29篇 |
1976年 | 26篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
2.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
3.
4.
5.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
6.
7.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(12):2271-2281
ObjectiveTo investigate the association between type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D) with risk of sudden cardiac arrest (SCA).MethodsIn a prospective community-based study of SCA from February 1, 2002, through November 30, 2019, we ascertained 2771 cases age 18 years of age or older and matched them to 8313 controls based on geography, age, sex, and race/ethnicity. We used logistic regression to evaluate the independent association between diabetes, T1D, T2D, and SCA.ResultsPatients had a mean age of 64.5±15.9 years, were 33.3% female and 23.9% non-White race. Overall, 36.7% (n=1016) of cases and 23.8% (n=1981) of controls had diabetes. Among individuals with diabetes, the proportion of T1D was 6.5% (n=66) among cases and 2.0% among controls (n=40). Diabetes was associated with 1.5-times higher odds of SCA. Compared with those without diabetes, the odds ratio and 95% CI for SCA was 4.36 (95% CI, 2.81 to 6.75; P<.001) in T1D and 1.45 (95% CI, 1.30 to 1.63; P<.001) in T2D after multivariable adjustment. Among those with diabetes, the odds of having SCA were 2.41 times higher in T1D than in T2D (95% CI, 1.53 to 3.80; P<.001). Cases of SCA with T1D were more likely to have an unwitnessed arrest, less likely to receive resuscitation, and less likely to survive compared with those with T2D.ConclusionType 1 diabetes was more strongly associated with SCA compared with T2D and had less favorable outcomes following resuscitation. Diabetes type could influence the approach to risk stratification and prevention of SCA. 相似文献
8.
慢性肾脏病是一种以肾脏功能的损伤为主要表现,并可累及全身多脏器的慢性进展性疾病。中医辨证治疗本病在延缓病情、改善预后等方面具有显著的优势。通过中医理论研究及临床经验总结,笔者提出从“肾毒”论治慢性肾脏病,认为其不仅是本病的致病因素,更是重要的病理产物,是本病发生发展、迁延难愈的关键。在治疗上提出以“益肾元、解肾毒”为大法,并根据不同兼夹辨证施治,采用药对,长治缓图。以“肾毒”立论拟定的经验方苏茵解毒方,在临床治疗和实验研究上均显示出明显的效果,并已制备成院内制剂临床使用,在疗效及经济效益方面均具有显著的优势。 相似文献
9.
10.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(6):714-721
SARS-CoV-2 pandemic has changed across the last 2 years. The development and approval of SARS-CoV-2 vaccines and the emergence of new variants has opened up a new scenario. On this regard, Spanish Society of Nephrology (S.E.N.) Council considers that an update of the previous recommendations should be performed. In the present statement, and taking into account the current epidemiological situation, are included updated recommendations of protection and isolation for patients on dialysis programs. 相似文献